Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 19/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 19/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14779845 | 1.00 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14779849 | 1.00 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14779718 | 0.90 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14779717 | 0.90 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14780426 | 0.89 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14780424 | 0.89 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14779913 | 0.87 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14779917 | 0.87 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL31260058 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14779926 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| CN-103814021-B | Dihydroquinoline 2 ketone derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-21 | — | — | CN | claimed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | claimed |
| CN-103814021-A | New dihydroquinoline-2-one derivatives | HOFFMANN LA ROCHE | 2014-05-21 | — | — | CN | claimed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | claimed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| CN-103814021-A | New dihydroquinoline-2-one derivatives | HOFFMANN LA ROCHE | 2014-05-21 | — | — | CN | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | CYP11B1 1089/4885CYP11B2 1068/4885CYP1A2 1578/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | CYP11B1 1/4885CYP11B2 2/4885CYP1A2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.